Clinical bottom line
Relapsed/refractory multiple myeloma (RRMM) remains a therapeutic challenge due to diverse resistance mechanisms limiting long-term efficacy of current treatments. Recent advances in novel agents targeting resistance pathways—particularly those directed at B-cell maturation antigen (BCMA), SLAMF7, and pro-survival signaling cascades—offer promising options to overcome resistance and improve outcomes. These agents include next-generation antibody-drug conjugates, bispecific antibodies, and small molecules designed to circumvent or directly counteract mechanisms of drug resistance. While early clinical data are encouraging, these therapies warrant further validation in larger, controlled trials to define optimal sequencing, combination strategies, and patient selection criteria.
What the evidence shows
Multiple myeloma cells exploit various resistance mechanisms, including antigen modulation, immune evasion, and activation of pro-survival pathways, which contribute to relapse after frontline and salvage therapies. BCMA has emerged as a critical target due to its near-universal expression on malignant plasma cells and limited normal tissue distribution. Shah et al. (2020) provide a comprehensive rationale for targeting BCMA, highlighting its role in myeloma cell survival and immune escape. Therapeutic modalities targeting BCMA now include antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies, with novel agents demonstrating efficacy in heavily pretreated RRMM populations (Shah et al., 2020; Tan et al., 2021).
SLAMF7, another surface antigen expressed on myeloma cells and natural killer cells, represents an additional target to overcome resistance. Boudreault et al. (2017) discuss SLAMF7’s dual role in tumor biology and immune modulation, supporting the use of SLAMF7-targeted therapies such as elotuzumab, which can enhance antibody-dependent cellular cytotoxicity and restore immune surveillance.
Beyond surface antigens, intracellular pro-survival signaling pathways, including NF-κB, PI3K/AKT/mTOR, and MAPK, contribute to drug resistance. Targeting these pathways with novel small molecules or combination regimens is an active area of investigation. Zhang et al. (2025) summarize emerging agents presented at the 2024 ASH meeting, noting promising early-phase data for inhibitors that disrupt these signaling cascades, potentially resensitizing myeloma cells to therapy.
Collectively, these novel agents address multiple resistance mechanisms, offering a multipronged approach to RRMM treatment. However, the heterogeneity of resistance pathways and patient-specific factors complicate therapeutic decision-making.
Caveats and uncertainty
Despite encouraging preliminary results, the evidence base for many novel agents targeting resistance mechanisms in RRMM remains early-stage, often limited to phase 1/2 trials with small cohorts and short follow-up. Long-term efficacy, durability of response, and safety profiles require further elucidation. Additionally, the optimal sequencing or combination of these agents with existing therapies is not yet established, and predictive biomarkers for response are lacking.
Resistance to BCMA-targeted therapies can develop via antigen loss or modulation, necessitating strategies to monitor and overcome such escape mechanisms. Similarly, immune-related adverse events and cytopenias remain concerns with immune-engaging agents. The complex interplay between tumor biology and host immunity underscores the need for personalized approaches and comprehensive clinical evaluation.
Finally, cost and accessibility of these novel therapies may limit widespread adoption, particularly in resource-constrained settings.
How this may change practice
The integration of novel agents targeting resistance mechanisms into RRMM management has the potential to extend progression-free and overall survival for patients who have exhausted standard options. Clinicians should remain informed about emerging data on BCMA- and SLAMF7-directed therapies, as well as inhibitors of pro-survival pathways, to identify candidates who may benefit from clinical trials or approved novel agents.
Future practice may involve biomarker-driven selection of resistance-targeted therapies and rational combination regimens to preempt or overcome resistance. Multidisciplinary collaboration and vigilant monitoring for adverse effects will be essential to optimize outcomes.
While these advancements are promising, incorporation into routine care should be guided by evolving evidence, regulatory approvals, and individual patient factors.